Indications for Acamprosate:
Maintenance of abstinence from alcohol in alcohol-dependent patients who are abstinent at treatment initiation, in conjunction with psychosocial support.
666mg 3 times daily. Renal impairment (CrCl 30–50mL/min): initially 333mg 3 times daily. Begin therapy during abstinence; continue during relapse.
Severe renal impairment (CrCl≤30mL/min). Sulfite allergy.
Moderate renal impairment (CrCl 31–50mL/min); reduce dose. Not a treatment for withdrawal symptoms. Monitor for suicidal ideation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
GI upset, myalgia/arthralgia, headache, rash, syncope, impotence, edema, palpitations; rare: kidney failure, suicidality.
Formerly known under the brand name Campral.